GPCR — Structure Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1888886 ·
Last close
$25.67
Market Cap
$1.83B
52W High
$94.90
52W Low
$25.09
ADV30
1,365,561
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -118,630,000 | -106,159,000 | 1,425,415,000 | 272,638,000 | 71,011,000 |
| Mar 2026 | 0 | — | -89,379,000 | -75,968,000 | 1,508,124,000 | 316,168,000 | 61,030,000 |
| Dec 2025 | 0 | — | 13,740,000 | 33,004,000 | 1,583,918,000 | 799,623,000 | 67,541,000 |
| Sep 2025 | 0 | — | -73,787,000 | -65,712,000 | 832,159,000 | 102,912,000 | 62,140,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-220,293,000
Investing CF
$-415,626,000
Financing CF
$761,533,000
CapEx
$-4,482,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.16
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-652,427,000
Inventory
—
Receivables
$0
ST Investments
$1,070,020,000
EBIT TTM
$-268,056,000
Pretax Income TTM
$-214,133,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -186,809,000 | -141,202,000 | 1,583,918,000 | 67,541,000 | 1,516,377,000 | -222,199,000 |
| Dec 2024 | 0 | -158,228,000 | -122,526,000 | 903,330,000 | 38,487,000 | 864,843,000 | -116,636,000 |
| Dec 2023 | 0 | -102,775,000 | -89,620,000 | 482,017,000 | 29,051,000 | 452,966,000 | -79,488,000 |
| Dec 2022 | 0 | -52,561,000 | -51,321,000 | 97,845,000 | 212,985,000 | -115,140,000 | -46,120,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-170,337,000
OpCashFlow TTM
—
Assets (Latest)
$1,508,124,000
Forward EPS
$-2.11
Max Pain — expiry 2026-10-16
max pain strike: $32.50 · spot: $25.54 · call oi: 2,798 · put oi: 1,119Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $1.83B | $12.82 | — |
| XNCR | Xencor Inc | $1.82B | $24.50 | — |
| URGN | UroGen Pharma Ltd. | $1.81B | $36.98 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.86B | $10.19 | — |
| BHVN | Biohaven Ltd. | $1.80B | $11.93 | — |
News headlines (Yahoo Finance, 1h cache)
Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
2026-09-22 11:13 · Yahoo
Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?
2026-09-10 23:46 · Yahoo
Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
2026-09-08 17:29 · Yahoo
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
2026-09-08 12:00 · Yahoo
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
2026-09-03 11:30 · Yahoo
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
2026-09-22 05:29 · Yahoo
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
2026-08-26 12:19 · Yahoo
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
2026-10-08 11:31 · Yahoo
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
2026-09-30 12:17 · Yahoo
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
2026-09-23 14:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.